Pharmacokinetics of indinavir at 800, 600, and 400 milligrams administered with ritonavir at 100 milligrams and efavirenz in ethnic chinese patients infected with human immunodeficiency virus.
We assessed the pharmacokinetics of three different doses of indinavir in five patients. All doses achieved trough concentrations above efficacy thresholds. Toxic trough concentrations were observed in all patients receiving 800 mg, in two patients receiving 600 mg, and in none receiving 400 mg. Indinavir at 400 mg may be efficacious and less toxic in patients taking ritonavir and efavirenz.
Lee
Lawrence S
LS
Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University, 600 N. Wolfe St., Osler 527, Baltimore, MD 21287, USA. llee3@jhsph.edu
Panchalingam
Anushia
A
Yap
Marline C
MC
Paton
Nicholas I
NI
D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D019540:Area Under Curve; D048588:Benzoxazines; D002681:China; D002851:Chromatography, High Pressure Liquid; D003521:Cyclopropanes; D004347:Drug Interactions; D015658:HIV Infections / Q000378:metabolism*; D006801:Humans; D019469:Indinavir / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000493:pharmacokinetics*; D019438:Ritonavir / Q000493:pharmacokinetics*
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D019469:Indinavir; C098320:efavirenz; D019438:Ritonavir